+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Neo-adjuvant chemotherapy in stage IIIC potentially resectable epithelial ovarian cancer



Neo-adjuvant chemotherapy in stage IIIC potentially resectable epithelial ovarian cancer



Gynecologic Oncology Reports 20: 131




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 066759930

Download citation: RISBibTeXText

PMID: 31061869

DOI: 10.1016/j.gore.2016.11.005


Related references

Stage IIIC epithelial ovarian cancer classified solely by lymph node metastasis has a more favorable prognosis than other types of stage IIIC epithelial ovarian cancer. Journal of Gynecologic Oncology 19(4): 223-228, 2008

Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer. Bulletin du Cancer 97(4): E23-E32, 2010

Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer. Gynecologic Oncology 124(1): 59-62, 2012

Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer. Medicine 95(36): E4797, 2016

Impact of neoadjuvant chemotherapy on the survival of patients with stage IIIc and IV epithelial ovarian cancer. Zhonghua Zhong Liu Za Zhi 30(4): 298-301, 2008

The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer. Radiology and Oncology 50(3): 341-346, 2016

Cost-effectiveness of primary debulking surgery when compared to neoadjuvant chemotherapy in the management of stage IIIC and IV epithelial ovarian cancer. Clinicoeconomics and Outcomes Research 8: 397-406, 2016

Neo-adjuvant chemotherapy does not increase the rate of complete resection and does not significantly reduce the morbidity of Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer. Gynecologic Oncology 138(2): 252-258, 2015

Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery: An Italian Multicenter Retrospective Study. International Journal of Gynecological Cancer 27(1): 28-36, 2017

Early evaluation of response to neoadjuvant chemotherapy in stage IIIC-IV epithelial ovarian cancer patients by 18 FDG-PET and CA 125: Preliminary findings from the Arianna Project 02. Journal of Clinical Oncology 24(18_Suppl): 15039-15039, 2016

Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer. Journal of Gynecologic Oncology 28(4): E48, 2017

Platinum-based adjuvant chemotherapy for early-stage epithelial ovarian cancer: single or combination chemotherapy?. Bjog 117(12): 1459-1467, 2010

Survival Advantage Associated with Decrease in Stage at Detection from Stage IIIC to Stage IIIA Epithelial Ovarian Cancer. Journal of Oncology 2014: 312193, 2014

Novel directions in adjuvant chemotherapy for early stage epithelial ovarian cancer. Asian Pacific Journal of Cancer Prevention 16(10): 4157-4160, 2015

Analysis of adjuvant chemotherapy in patients with Stage-III epithelial ovarian cancer. Zhongguo Zhongliu Linchuang 31(3): 141-143, 2004